Details for Patent: 9,163,043

Title:	Oxazolidinone derivatives
Abstract:	The present invention relates to novel derivatives of oxazolidinone, a method thereof and pharmaceutical compositions comprising the derivatives for use in an antibiotic. The oxazolidinone derivatives of the present invention show inhibitory activity against a broad spectrum of bacteria and lower toxicity. The prodrugs, prepared by reacting the compound having hydroxyl group with amino acid or phosphate, have an excellent efficiency on solubility thereof against water. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium. Accordingly, the compositions comprising the oxazolidinone are used in an antibiotic.
Inventor(s):	Rhee; Jae Keol (Kyonggido, KR), Im; Weon Bin (Kyunggi-do, KR), Cho; Chong Hwan (Yongin-si, KR), Choi; Sung Hak (Seongnam-si, KR), Lee; Tae Ho (Yongin-si, KR)
Assignee:	DONG-A ST CO., LTD. (Seoul, KR)
Filing Date:	Apr 15, 2013
Application Number:	13/863,216
Claims:	1. An oxazolidinone derivative of Formula I, or a pharmaceutically acceptable salt thereof; ##STR00078## wherein, Het is pyrrolyl, imidazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, pyrazolyl, pyrrolidinyl, oxazolyl, isoxazolyl, or thiazolyl; X is carbon; ring A is unsubstituted or has at least one fluorine substituent; R.sub.7 is H, PO(OH).sub.2, or PO(O).sub.2.sup.-2(M.sup.+).sub.2, wherein M.sup.+ is a pharmaceutically acceptable metal cation; wherein Het is unsubstituted or optionally substituted with one or more R.sub.3, wherein R.sub.3 is at least one C.sub.1-4 alkyl group that is unsubstituted, or substituted with cyano, --(CH.sub.2)m-OR.sub.7 or ketone; and m is 0, 1, 2, 3, or 4. 2. The oxazolidinone derivative of claim 1 or a pharmaceutically acceptable salt thereof, wherein M.sup.+ is Na.sup.+. 3. The oxazolidinone derivative of claim 1 or a pharmaceutically acceptable salt thereof, wherein Het is 1,2,4-triazolyl or 1,2,3-triazolyl. 4. An oxazolidinone derivative which is ##STR00079## or a pharmaceutically acceptable salt thereof; wherein R.sub.1 and R.sub.1' are each independently H or F; Het is pyrrolyl, imidazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, pyrazolyl, pyrrolidinyl, oxazolyl, isoxazolyl, or thiazolyl; X is carbon; R.sub.7 is H, PO(OH).sub.2, or PO(O).sub.2.sup.-2(M.sup.+).sub.2, wherein M.sup.+ is a pharmaceutically acceptable metal cation; wherein Het is unsubstituted or optionally substituted with one or more R.sub.3, wherein R.sub.3 is at least one C.sub.1-4 alkyl group that is unsubstituted, or substituted with cyano, --(CH.sub.2)m-OR.sub.7 or ketone; and m is 0, 1, 2, 3, or 4. 5. A pharmaceutical composition comprising the oxazolidinone derivative of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 6. The pharmaceutical composition of claim 5, wherein the pharmaceutical composition is an injectable composition. 7. A method of treating a bacterial infection in a subject, comprising administering to the subject the oxazolidinone derivative of claim 1 or a pharmaceutically acceptable salt thereof. 8. The method of claim 7, wherein the bacterium is selected from the group consisting of Staphylococcus, Enterococcus, and Streptococcus. 9. The method of claim 8, wherein the bacterium is MRSA or VRE. 10. A pharmaceutical composition comprising the oxazolidinone derivative of claim 4 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 11. The pharmaceutical composition of claim 10, wherein the pharmaceutical composition is an injectable composition. 12. A method of treating a bacterial infection in a subject, comprising administering to the subject the oxazolidinone derivative of claim 4 or a pharmaceutically acceptable salt thereof. 13. The method of claim 12, wherein the bacterium is selected from the group consisting of Staphylococcus, Enterococcus, and Streptococcus. 14. The method of claim 13, wherein the bacterium is MRSA or VRE. 15. The oxazolidinone derivative of claim 4, wherein Het is 1,2,4-triazolyl, or 1,2,3-triazolyl. 16. The oxazolidinone derivative of claim 1 or a pharmaceutically acceptable salt thereof wherein Het is unsubstituted or optionally substituted with one or two R.sub.3. 17. The oxazolidinone derivative of claim 4 or a pharmaceutically acceptable salt thereof wherein Het is unsubstituted or optionally substituted with one or two R.sub.3. 18. The oxazolidinone derivative of claim 1 or a pharmaceutically acceptable salt thereof, wherein Het is thiazolyl. 19. The oxazolidinone derivative of claim 4 or a pharmaceutically acceptable salt thereof, wherein Het is thiazolyl. 20. A compound which is ##STR00080## or a pharmaceutically acceptable salt thereof.